A Study of Ixekizumab (LY2439821) in Chinese Participants With Moderate-to-Severe Plaque Psoriasis
Status:
Completed
Trial end date:
2020-06-04
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the efficacy and safety of the study drug
ixekizumab in Chinese participants with moderate-to-severe plaque psoriasis.